UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000059773
Receipt number R000067801
Scientific Title A Study on the Effects of Continuous Intake of a Food Product on Physical and Mental Health
Date of disclosure of the study information 2025/11/14
Last modified on 2025/11/11 20:03:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Study on the Effects of Continuous Intake of a Food Product on Physical and Mental Health

Acronym

A Study on the Effects of Continuous Intake of a Food Product on Physical and Mental Health

Scientific Title

A Study on the Effects of Continuous Intake of a Food Product on Physical and Mental Health

Scientific Title:Acronym

A Study on the Effects of Continuous Intake of a Food Product on Physical and Mental Health

Region

Japan


Condition

Condition

Healthy adult male

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm the effects of continuous intake of the test food on physical and mental health.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Blood Metabolomics

Key secondary outcomes

Daily log (frequency of bowel movements, stool characteristics), Profile of mood states 2nd edition, VAS (Visual Analog Scale) questionnaire, Lifestyle questionnaire, PSQI (Pittsburgh Sleep Quality Index), SWLS (Satisfaction with Life Scale) (Japanese version), Hematological tests, Blood biochemical tests, Salivary cortisol, Salivary serotonin, Salivary oxytocin, Stratum corneum water content, Transepidermal water loss (TEWL), Skin viscoelasticity, Gut microbiota, Fecal short-chain fatty acids (SCFAs), Blood BDNF (Brain-derived neurotrophic factor)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Oral consumption of the test food (4 pieces per time, twice daily) for 4 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

40 years-old >

Gender

Male

Key inclusion criteria

1. Healthy males aged 30 to below 40 years at the time of consent acquisition.
2. Individuals with a body mass index (BMI) of 18.5 kg/m2 or higher and less than 25.0 kg/m2.
3. Individuals who constantly perceive daily stress.
4. Individuals who spend 30 minutes or more outdoors during the day (e.g., during commuting) without sunglasses.
5. Individuals who are able to give informed consent to participate in this study after receiving a detailed explanation of the protocol and understanding its contents.

Key exclusion criteria

1. Individuals who regularly consume Foods for Specified Health Uses, Foods with Function Claims, or health foods (including supplements) that may affect the study (including sleep improvement and stress reduction claims) and are unable to discontinue use from one month before the pre-examination and test food intake.
2. Individuals who take medications (e.g., antibiotics, laxatives, gastrointestinal drugs) that may affect the study and who cannot restrict their use during the study period.
3. Individuals who are receiving medical care or drug treatment for a disease that may affect the study.
4. Individuals diagnosed with severe anemia based on pre-examination blood test results.
5. Individuals with a habit of consuming foods/beverages containing cacao, cocoa, or cocoa butter (once a week or more).
6. Individuals who dislike chocolate.
7. Individuals with bruises or scars on the skin measurement area (inner side of the left forearm).
8. Individuals who are participating in, have participated in within the four weeks prior to the current trial, or are planning to participate in clinical trials of pharmaceuticals or health foods.
9. Individuals with extremely irregular lifestyles (such as night shifts, irregular shift work, or irregular sleep habits).
10. Individuals with excessive alcohol intake.
11. Individuals who are in the habit of smoking, or have been in the habit of smoking within the past six months.
12. Individuals who, at the time of consent acquisition, have plans involving significant changes in lifestyle or sleep habits (e.g., overseas business trips of 2 weeks or longer) during the study period.
13. Individuals who will develop hay fever symptoms during the study period, or who plan to take medication during the same period.
14. Individuals with previous and/or current medical history of serious diseases in the heart, liver, kidney, digestive organs, etc., (including perioperative period).

Target sample size

24


Research contact person

Name of lead principal investigator

1st name Fumiko
Middle name
Last name Nakamura

Organization

CPCC Company Limited

Division name

Clinical Support Department

Zip code

103-0021

Address

4F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo, Japan

TEL

03-6225-9001

Email

cpcc-contact@cpcc.co.jp


Public contact

Name of contact person

1st name Masanori
Middle name
Last name Numa

Organization

CPCC Company Limited

Division name

Clinical Planning Department

Zip code

103-0021

Address

4F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo, Japan

TEL

03-6225-9001

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

LOTTE CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan

Tel

03-6225-9005

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 11 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2025 Year 10 Month 29 Day

Date of IRB

2025 Year 10 Month 24 Day

Anticipated trial start date

2025 Year 11 Month 17 Day

Last follow-up date

2026 Year 03 Month 26 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

(Exclusion criteria continued)
15. Individuals with allergies to medications and/or food (specifically eggs, wheat, cacao, milk, and soybeans).
16. Individuals who donated 200 mL of his blood or blood components within the last month.
17. Individuals who donated 400 mL of his blood within the last 3 months.
18. Individuals who have had a total of 1200 mL of his blood collected within the last 12 months, including in this study.
19. Individuals deemed unsuitable for participation in the trial by the principal investigator or sub-investigator.


Management information

Registered date

2025 Year 11 Month 14 Day

Last modified on

2025 Year 11 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000067801